CARB-X funds Peptilogics to develop a new class of antibiotics to treat serious superbug infections associated with implants
CARB-X is awarding Peptilogics, headquartered in Pittsburgh, USA, up to US$2.56 million in non-dilutive funding to develop a new class of peptide antibiotics with broad activity against drug-resistant bacteria. The company could receive up to $9.61 million more in additional funding if the project achieves certain development milestones, for a potential total of up to $12.17 million.
The initial application of the new antibiotic would be towards serious infections associated with implants such as prosthetic knees and hips. CARB-X funding will support the development of Peptilogics’ lead compound PLG0206, including the filing of a US Food and Drug Administration (FDA) Investigational New Drug (IND) Application and Phase 1 clinical trial.
Emerging Antimicrobials and Diagnostics in AMR 2023
International Matchmaking Symposium EADA 2023
Amsterdam, The Netherlands